DOCSLIB.ORG

The New Class War: SGLT2 Inhibitors Versus DPP-4 Inhibitors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The New Class War: SGLT2 Inhibitors Versus DPP-4 Inhibitors ARTICLE The new class war: SGLT2 inhibitors versus DPP-4 inhibitors Merlin Thomas Over 90% of people with type 2 diabetes will need more than metformin monotherapy Citation: Thomas M (2017) The new class war: SGLT2 inhibitors versus to achieve their targets for optimal glucose levels. There are many second-line options for DPP-4 inhibitors. Diabetes & Primary glucose management in type 2 diabetes, including the sodium–glucose cotransporter 2 Care Australia 2: 119 –23 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor classes. This article provides Article points a framework for Australian general practices to compare the associated benefits and risks 1. Over 90% of people with of SGLT2 inhibitors and DPP-4 inhibitors when added to metformin for the management type 2 diabetes will require of type 2 diabetes. additional medication after metformin. 2. Dipeptidyl peptidase-4 ver 90% of people with type 2 Question #1: efficacy inhibitors and sodium–glucose diabetes will need more than The most obvious first question when deciding cotransporter 2 inhibitors metformin monotherapy to achieve between an SGLT2 and a DPP-4 inhibitor is how provide an alternative O to the older glucose- their targets for optimal glucose levels. Dual well does each class lower glucose? Across clinical lowering medications. therapy may begin early in their management, trials, SGLT2 inhibitors have been shown to lower 3. Drug regimens should when it is clear that metformin is insufficient HbA1c by 7.2 mmol/mol (−0.66%; 95% confidence be individualised and (primary failure) or later as the efficacy of interval [CI], −0.73%, −0.58%; Vasilakou et patient-centred. metformin gradually wanes (secondary failure). al, 2013). Very similar results have also been The Royal Australian College of General reported for DPP-4 inhibitors in participants Key words Practitioners (RACGP) and Diabetes Australia who were not achieving their glycaemic target – DPP-4 inhibitors (2014) guidelines recommend that when on metformin alone (7.2 mmol/mol [−0.69%] – Dual therapy optimal glycaemic levels are not met, no more 95% CI, −0.79%, −0.61%; Liu et al, 2012). It – SGLT2 inhibitors than 3–6 months should pass before a second- has been considered that there is no significant line agent is added. Of course, earlier initiation difference in glucose lowering achieved by either of combination therapy may be appropriate in drug class (Goring et al, 2014). However, recent some cases, especially when diabetes is clearly head-to-head studies have suggested that SGLT2 managed suboptimally. inhibitors may result in a greater glucose-lowering There are many second-line options for effect than DPP-4 inhibitors in people with type 2 glucose management of type 2 diabetes, diabetes very suboptimally managed diabetes at including the sodium–glucose cotransporter 2 baseline (HbA1c >75 mmol/mol [9%]; Rosenstock (SGLT2) inhibitor and dipeptidyl peptidase-4 et al, 2014; DeFronzo et al, 2015). In contrast, for (DPP-4) inhibitor classes. These newer classes people with type 2 diabetes who have an HbA1c have a number of advantages compared around 53 mmol/mol (7%), a DPP-4 inhibitor to older classes, including reduced risk of may achieve a greater glucose-lowering effect. hypoglycaemia and weight gain, and no need The effect of DPP-4 inhibitors on fasting plasma for dose-titration. So the question, rather than glucose may be modestly greater than with SGLT2 whether to use them, is which agent will be inhibitors in combination with metformin, while best for the patient you have in front of you? the converse may be true for post-prandial glucose This article provides a framework to compare levels (Rosenstock et al, 2014; DeFronzo et al, the associated benefits and risks of SGLT2 2015). In people with type 2 diabetes who have Author inhibitors and DPP-4 inhibitors, when added renal impairment, there may be a reduction in Merlin Thomas is Professor, Department of Diabetes, to metformin for the management of type 2 SGLT2 inhibitor efficacy. The glucose-lowering Central Clinical School, Monash diabetes in Australian general practice. effects of DPP-4 inhibitors are unaffected or University, Melbourne. Diabetes & Primary Care Australia Vol 2 No 3 2017 119 © OmniaMed SB and the Primary Care Diabetes Society of Australia – www.pcdsa.com.au The new class war Page points even modestly improved in people with renal The modest volume losses associated with 1. DPP-4 inhibitors have highly impairment (Thomas et al, 2016). SGLT2 inhibition should not cause dehydration, favourable tolerability. This is constipation or dizziness in the long term (Vasilakou important, as most Australians with type 2 diabetes are over Question #2: tolerability et al, 2013). However, alternative glucose-lowering 65 years of age, and for whom All treatments have the potential for adverse strategies should be considered for individuals polypharmacy, inconstant effects, so the doctor’s mantra must be prius minus prone to postural hypotension, fainting or dizziness. health and comorbidities are common. noceant (first do least harm). The key advantage of About 1 in 12 women with diabetes using 2. Because of their mode of using DPP-4 inhibitors is their highly favourable an SGLT2 inhibitor will develop genital thrush action, SGLT2 inhibitors are tolerability (Karagiannis et al, 2012; Kawalec et (candidiasis), usually in the first 3–4 months of not recommended for glucose al, 2014). This is critical, given that the most treatment (Wilding, 2014). Thrush is easy to lowering in people with renal Australians with type 2 diabetes are over 65 years recognise and treat with short courses of standard impairment. of age, in whom polypharmacy, inconstant health antifungal therapies (topical creams, suppositories 3. While some antidiabetes medications are potentially and comorbidities are common. Recent studies or oral “azoles”). Once treated, recurrent infections weight promoting, DPP-4 have confirmed a very small risk of pancreatitis with are uncommon. Although SGLT2 inhibitors inhibitors are weight neutral DPP-4 inhibitors (DeVries et al, 2017). add glucose to the urine, surprisingly, urinary and SGLT2 inhibitors are weight negative. SGLT2 inhibitors block the SGLT2 protein tract infections (UTIs) are not significantly more involved in 90% of glucose reabsorption in the common or more severe in participants receiving proximal renal tubule, resulting in increased renal SGLT2 inhibitors, even in women with a previous glucose excretion and lower blood glucose levels. history of chronic or recurrent UTIs (Vasilakou et SGLT2 inhibitors also increase the urine output, al, 2013). This is possibly because people taking an especially when therapy has just been started and SGLT2 inhibitor empty their bladder more often, glucose levels are high. This can be a positive and just like encouraging drinking, this reduces experience for people using an SGLT2 inhibitor, as bladder stasis and offsets the risk of UTIs. within hours of taking the drug, it begins to take effect. As glucose levels improve, the amount and Question #3: optimising body weight frequency of urination usually settles down. Optimising body weight is a key element of the The glucose-lowering efficacy of SGLT2 management of type 2 diabetes in overweight or obese inhibitors is dependent on sufficient glomerular people, especially in early diabetes when weight loss is filtration to deliver a glucose load to the proximal a high priority and can be hard to achieve, reinforce tubule. SGLT2 inhibitors are not recommended or sustain. When glucose levels are suboptimal, it is for glucose lowering in patients with renal common to recommend intensification of lifestyle impairment (estimated glomerular filtration rate interventions to lose weight while also adding in [eGFR] <45 mL/min/1.73 m2 for empagliflozin or additional glucose-lowering agents. It is important <60 mL/min/1.73 m2 for dapagliflozin), although to be aware that some antidiabetes medications are action on weight, renal and cardiac outcomes potentially weight promoting (sulfonylureas, insulin appear to be maintained even in patients with and thiazolidinediones), and so will be antagonist severe renal impairment. with the advice to intensify lifestyle interventions In the long-term, people with type 2 diabetes for weight loss. DPP-4 inhibitors are weight neutral taking SGLT2 inhibitors will void on average an while SGLT2 inhibitors are weight negative. Glucose extra 300–400 mL/day (Kilov et al, 2013). This is loss and thus calorie loss in the urine, as a result of the same volume as a can of soft drink and taking an an SGLT2 inhibitor, can result in rapid, significant SGLT2 inhibitor will generally mean individuals will and sustained weight loss (approximately 2–3 kg go to the toilet once or maybe twice more every day, in 6 months). Most of the weight loss seen with especially if the medication is taken in the morning SGLT2 inhibition is loss of fat, including visceral (Johnsson et al, 2013). Individuals with type 2 fat (Bolinder et al, 2012), which is important for diabetes who have pre-existing bladder, pelvic floor the waistline and overall health. Interestingly, after or prostate problems may not feel comfortable with 6 months of SGLT2 inhibition, weight loss stops any increase in their urine output, and other glucose- even though glycosuria continues. SGLT2 inhibition lowering strategies should be considered. can contribute to weight loss, but is not the solution. 120 Diabetes & Primary Care Australia Vol 2 No 3 2017 © OmniaMed SB and the Primary Care Diabetes Society of Australia – www.pcdsa.com.au The new class war Question #4: cardiovascular safety of Vascular Outcomes Recorded in Patients with Page points Reducing the risk of cardiovascular events is a Diabetes Mellitus – Thrombolysis in Myocardial 1. Cardiovascular safety data for priority of diabetes management as heart attacks Infarction; Mosenzon et al, 2017) and TECOS DPP-4 inhibitors suggest that the class does not pose an and strokes account for over a third of all deaths (Trial Evaluating Cardiovascular Outcomes with unacceptable cardiovascular in people with type 2 diabetes.
Load more

Recommended publications
  • Think Medicines!
    Think Issue 13 August 2016 MHRA Drug Safety SGLT2 inhibitors: updated advice on the risk of diabetic Medicines!Updates can be found ketoacidosis (DKA) at the following link. The MHRA are advising health care professionals to test for raised ketones in patients with ketoacidosis symptoms, who are taking SGLT2 inhibitors even if New higher strength Humalog® plasma glucose levels are near-normal. SGLT2 inhibitors include: Canagliflozin, 200 units/ml KwikPen™ Dapagliflozin and Empagliflozin. Serious, life-threatening, and fatal cases of In order to minimize medication DKA have been reported in patients taking an SGLT2 inhibitor. In several cases, errors. blood glucose levels were only moderately elevated (e.g. <14mmol/L) Insulin lispro 200 units/ml representing an atypical presentation for DKA, which could delay diagnosis and solution for injection should treatment. ONLY be administered using the Advice for health Care Professionals: Humalog 200 units/ml pre-filled Inform patients of the signs of diabetic ketoacidosis (DKA) and advise them to pen (KwikPen). seek immediate medical advice if they develop any of these symptoms (e.g. When switching from one rapid weight loss, feeling sick or being sick, stomach pain, fast and deep Humalog strength to another, breathing, sleepiness, a sweet smell to the breath, a sweet or metallic taste in the dose does not need to be the mouth, or a different odour to urine or sweat). converted. Unnecessary dose Discuss the risk factors of DKA with patients. conversion may lead to under/ Discontinue treatment with the SGLT2 inhibitor immediately if DKA is over dosing and resultant hyper/ suspected or diagnosed.
    [Show full text]
  • IHS PROVIDER September 2017
    September 2017 Volume 42 Number 9 Indian Health Service National Pharmacy and Therapeutics Committee SGLT-2 inhibitors (Update) NPTC Formulary Brief August Meeting 2017 Background: The FDA has currently approved three SGLT-2 inhibitors, two of which have completed FDA-mandated cardiovascular outcomes trials. Last year, in the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG), empagliflozin not only reduced cardiovascular events, but also mortality.1 This year, the Canagliflozin Cardiovascular Assessment Study (CANVAS) demonstrated equivocal cardiovascular benefits, no mortality benefit, and significant harms in those receiving canagliflozin.2 The DECLARE-TIMI 58 cardiovascular study of dapagliflozin will be completed in April 2019 (ClinicalTrials.gov Identifier: NCT01730534). Uncertainty remains regarding the current data, long- term benefits and harms, and differentiation among SGLT-2 inhibitors. Following a review of SGLT2 inhibitors at the August 2017 NPTC meeting on their cardiovascular outcomes, net benefit and place in therapy, no modifications were made to the National Core Formulary (NCF). Discussion: EMPA-REG enrolled 7,020 patients with Type 2 diabetes mellitus (T2DM) and HgbA1c values between 7.0-10.0%. All patients had established cardiovascular disease (CVD) and were observed for a median duration of 3.1 years. Empagliflozin reduced the primary outcome of cardiovascular (CV) death, nonfatal myocardial infarction (MI), or nonfatal cardiovascular accident (CVA) by 6.5 events per 1000 patient-years (pt-yrs). Mortality decreased by 9.2 events per 1000 pt-yrs, primarily driven by a reduction in CV mortality of 7.8 events per 1000 pt-yrs. Heart failure hospitalization decreased by 5.1 events per 1000 pt-yrs.
    [Show full text]
  • Step Therapy
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2020 P 3086-9 Program Step Therapy – Diabetes Medications - SGLT2 Inhibitors Medication Farxiga (dapagliflozin)*, Glyxambi (empagliflozin/linagliptan), Invokana (canagliflozin)*, Invokamet (canagliflozin/metformin)*, Invokamet XR (canaglifloxin/metformin extended-release)*, Jardiance (empagliflozin), Qtern (dapagliflozin/saxagliptin)*, Segluromet (ertugliflozin/metformin)*, Steglatro (ertugliflozin)*, Steglujan (ertugliflozin/sitagliptin)*, Xigduo XR (dapagliflozin/metformin extended-release)* P&T Approval Date 10/2016, 10/2017, 4/2018, 8/2018, 12/2018, 2/2019, 2/2020, 5/2020; 7/2020 Effective Date 10/1/2020; Oxford only: 10/1/2020 1. Background: Farxiga (dapagliflozin)*, Invokana (canagliflozin)*, Jardiance (empagliflozin) and Steglatro (ertugliflozin)* are sodium-glucose co-transporter 2 (SGLT2) inhibitors indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Farxiga*, Invokana* and Jardiance have additional indications. Farxiga* is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction. Invokana* is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD), and to reduce the risk of end-stage kidney disease (ESKD), doubling of
    [Show full text]
  • SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
    Journal of Clinical Medicine Editorial SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease Swetha R. Kanduri 1 , Karthik Kovvuru 1, Panupong Hansrivijit 2 , Charat Thongprayoon 3, Saraschandra Vallabhajosyula 4, Aleksandra I. Pivovarova 5 , Api Chewcharat 3, Vishnu Garla 6, Juan Medaura 5 and Wisit Cheungpasitporn 3,5,* 1 Department of Nephrology, Ochsner Medical Center, New Orleans, LA 70121, USA; [email protected] (S.R.K.); [email protected] (K.K.) 2 Department of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, PA 17105, USA; [email protected] 3 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA; [email protected] (C.T.); [email protected] (A.C.) 4 Section of Interventional Cardiology, Division of Cardiovascular Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA; [email protected] 5 Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39156, USA; [email protected] (A.I.P.); [email protected] (J.M.) 6 Department of Internal Medicine and Mississippi Center for Clinical and Translational Research, University of Mississippi Medical Center, Jackson, MS 39156, USA; [email protected] * Correspondence: [email protected] Received: 20 August 2020; Accepted: 20 August 2020; Published: 24 August 2020 Abstract: Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive effects of SGLT2i are centered on multiple mechanisms, including glycosuric effects, tubule—glomerular feedback, antioxidant, anti-fibrotic, natriuretic, and reduction in cortical hypoxia, alteration in energy metabolism.
    [Show full text]
  • Ertugliflozin 5Mg, 15Mg Film-Coated Tablet (Steglatro®) Merck Sharp & Dohme
    1 www.scottishmedicines.org.uk SMC2102 ertugliflozin 5mg, 15mg film-coated tablet (Steglatro®) Merck Sharp & Dohme 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission ertugliflozin (Steglatro®) is accepted for restricted use within NHSScotland. Indication under review: in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. In addition to other medicinal products for the treatment of diabetes. SMC restriction: ertugliflozin is accepted for use as monotherapy and as add-on therapy. When used as monotherapy it is restricted to patients who would otherwise receive a dipeptidyl peptidase-4 inhibitor and in whom a sulphonylurea or pioglitazone is not appropriate. Ertugliflozin was superior to placebo in lowering HbA1c in adults with type 2 diabetes mellitus in phase III studies in monotherapy, dual therapy and triple therapy settings. Chairman Scottish Medicines Consortium Published 14 January 2019 1 Indication In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. In addition to other medicinal products for the treatment of diabetes.1 Dosing Information The recommended starting dose is 5mg orally once daily which can, if tolerated, be increased to 15mg once daily if additional glycaemic control is needed.
    [Show full text]
  • PRODUCT INFORMATION Ipragliflozin Item No
    PRODUCT INFORMATION Ipragliflozin Item No. 22287 CAS Registry No.: 761423-87-4 OH Formal Name: (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien- 2-ylmethyl)-4-fluorophenyl]-D-glucitol OH Synonym: ASP1941 O MF: C21H21FO5S FW: 404.5 S OH Purity: ≥98% OH UV/Vis.: λmax: 231, 267 nm Supplied as: A crystalline solid F Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Ipragliflozin is supplied as a crystalline solid. A stock solution may be made by dissolving the ipragliflozin in the solvent of choice. Ipragliflozin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of ipragliflozin in these solvents is approximately 30 mg/ml. Ipragliflozin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ipragliflozin should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Ipragliflozin has a solubility of approximately 0.13 mg/ml in a 1:7 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Ipragliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 7.4 nM in CHO cells expressing the human cotransporter).1 It is selective for SGLT2 over SGLT1, SGLT3, SGLT4, SGLT5, and SGLT6 (IC50s = 1.9, 30.4, 15.9, 0.46, and 10.4 µM, respectively). Ipragliflozin (0.1-3 mg/kg) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in a mouse model of diabetes induced by high-fat diet, streptozotocin (STZ; Item No.
    [Show full text]
  • SGLT2) Inhibitors (Gliflozins) in Adults with Type 2 Diabetes (T2DM
    Sodium-glucose cotransporter-2 (SGLT2) inhibitors (Gliflozins) in Adults with Type 2 Diabetes (T2DM) There are currently four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and ertugliflozin) licensed in the UK for the management of adults with T2DM. No head to head trials between the SGLT2 inhibitors have been conducted. As at December 2019, clinical outcome data is available for three of the four SGLT2 inhibitors around their cardiovascular effects in people with T2DM. Ertugliflozin is still to report on this data. This document summarises the key prescribing considerations. NICE Technology Appraisal Recommendation NICE makes recommendations for when SGLT2 inhibitors can be considered in adults with T2DM; Hertfordshire Medicines Management Committee Recommendations are in line with NICE guidance: Monotherapy NICE TA 390: Canagliflozin, Dapagliflozin and Empagliflozin and NICE TA 572: Ertugliflozin as monotherapies for treating T2DM Monotherapy recommended as option in adults for whom metformin is contraindicated or not tolerated and when diet & exercise alone do not provide adequate glycaemic control, only if: •a DPP‑4 inhibitor would otherwise be prescribed and •a sulfonylurea or pioglitazone is not appropriate. Dual therapy NICE TA 315: Canagliflozin, NICE TA288: Dapagliflozin, TA 336: Empagliflozin, TA 572: Ertugliflozin as combination therapies for treating T2DM In a dual therapy regimen in combination with metformin is recommended as an option, only if: •a sulfonylurea is contraindicated or not tolerated or •the person is at significant risk of hypoglycaemia or its consequences. In combination with insulin NICE TA 315: Canagliflozin, NICE TA288: Dapagliflozin, TA 336: Empagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option.
    [Show full text]
  • SGLT2 Inhibitors in Combination Therapy: from Mechanisms To
    Diabetes Care Volume 41, August 2018 1543 Michael¨ J.B. van Baar, SGLT2 Inhibitors in Combination Charlotte C. van Ruiten, Marcel H.A. Muskiet, Therapy: From Mechanisms to Liselotte van Bloemendaal, Richard G. IJzerman, and PERSPECTIVES IN CARE Clinical Considerations in Type 2 Daniel¨ H. van Raalte Diabetes Management Diabetes Care 2018;41:1543–1556 | https://doi.org/10.2337/dc18-0588 The progressive nature of type 2 diabetes (T2D) requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic targets are not attained. With guidelines moving away from a one-size-fits-all approach toward setting patient-centered goals and allowing flexibility in choosing a second-/ third-line drug from the growing number of U.S. Food and Drug Administration– approved glucose-lowering agents, keen personalized management in T2D has become a challenge for health care providers in daily practice. Among the newer generation of glucose-lowering drug classes, sodium–glucose cotransporter 2 inhibitors (SGLT2is), which enhance urinary glucose excretion to lower hyper- glycemia, have made an imposing entrance to the T2D treatment armamentarium. Given their unique insulin-independent mode of action and their favorable efficacy– to–adverse event profile and given their marked benefits on cardiovascular-renal outcome in moderate-to-high risk T2D patients, which led to updates of guidelines and product monographs, the role of this drug class in multidrug regimes is promising. However, despite many speculations based on pharmacokinetic and pharmacodynamic properties, physiological reasoning, and potential synergism, the effects of these agents in terms of glycemic and pleiotropic efficacy when combined with other glucose-lowering drug classes are largely understudied.
    [Show full text]
  • ANTI-HYPERGLYCEMIC DIABETES AGENTS in T2DM: Color Outcomes Comparison Summary Table
    ANTI-HYPERGLYCEMIC DIABETES AGENTS in T2DM: Outcomes Comparison Summary Table L Regier BSP BA, M LeBras PharmD, T Trischuk PharmD, J Bareham BSP, L Lu BSP © www.RxFiles.ca Aug 2021 Drug Class Sulfonylureas TZDs Meglitinides DPP4 Inhibitors GLP1 Agonists *** SGLT2 Inhibitors *** Insulin in T2DM Generic Metformin Gliclazide Glyburide Pioglitazone Rosiglitazone Acarbose Repaglinide Saxagliptin ONGLYZA Liraglutide VICTOZA Empagliflozin JARDIANCE Intensity: Intensity: BRAND (MF) DIAMICRON DIABETA ACTOS, g AVANDIA GLUCOBAY GLUCONORM Sitagliptin JANUVIA Exenatide BYETTA, BYDUREON Canagliflozin INVOKANA Less More GLUCOPHAGE Dulaglutide TRULICITY Dapagliflozin FORXIGA, FARXIGA Alogliptin NESINA (e.g. NPH (Multiple daily GLUCOTROL D/C STEGLATRO Glipizide Nateglinide Semaglutide OZEMPIC, RYBELSUS (PO) Ertugliflozin Linagliptin TRAJENTA HS + MF) doses) STARLIX D/C SPREAD-DIMCAD] Lixisenatide ADLYXINE; ALBIGLUTIDE D/C SAVOR-TIMI 53, EMPA-REG, CANVAS, CREDENCE, T2DM: UKPDS-33,80; ADVANCE, Major trials to UKPDS- ProACTIVE ACE 33,34,80 UKPDS- Meta-analysis. TECOS, EXAMINE LEADER, EXSCEL, FREEDOM CVO, DECLARE, VERTIS-CV (2020), ACCORD, VADT, ORIGIN, DEVOTE support ADVANCE (Prevention (ADOPT; 33,80 Ferwana M. Meta- RECORD interim, PROLOGUE, REWIND, SUSTAIN-6, PIONEER-6, DAPA-HF, DAPA-CKD (2020), T1DM: DCCT/EDIC findings/ analysis 2013. trial: Stop- - some use in (ADOPT) ADOPT, DREAM CARMELINA, EMPEROR-Reduced & -Preserved (Also Boussageon et al. Meta- Outcomes* ADVANCE) SR-Liao 2017; IRIS NIDDM) ELIXA, HARMONY CAROLINA (2020), EMPA-Kidney (2022) analysis.
    [Show full text]
  • Cost-Effectiveness of Empagliflozin Versus Canagliflozin, Dapagliflozin
    Emerging technologies, pharmacology and therapeutics Open access Original research BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2020-001313 on 3 May 2021. Downloaded from Cost-­effectiveness­of­empagliflozin­ versus­canagliflozin,­dapagliflozin,­or­ standard­of­care­in­patients­with­type­2­ diabetes­and­established­ cardiovascular­disease Odette S Reifsnider ,1 Anuraag R Kansal,1 Pranav K Gandhi,2 Lael Cragin,1 Sarah B Brand,1 Egon Pfarr,3 Kyle Fahrbach,4 Anastasia Ustyugova3 To cite: Reifsnider OS, ABSTRACT Kansal AR, Gandhi PK, Introduction Empagliflozin, a sodium- glucose co- Significance of this study et al. Cost- effectiveness transporter-2 (SGLT-2) inhibitor, is approved in the USA of empagliflozin versus to reduce risk of cardiovascular (CV) death in adults What is already known about this subject? canagliflozin, dapagliflozin, with type 2 diabetes mellitus (T2DM) and established CV ► The sodium glucose co- transporter-2 inhibitor (SGLT- or standard of care in 2) empagliflozin is Food and Drug Administration patients with type 2 disease, based on EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes (FDA) approved to reduce the risk of cardiovascular diabetes and established (CV) death in adults with type 2 diabetes mellitus cardiovascular disease. Mellitus Patients) trial results. Empagliflozin reduced major (T2DM) and established CV disease (CVD) based BMJ Open Diab Res Care adverse CV event (MACE) by 14%, CV death by 38%, and 2021;9:e001313. doi:10.1136/ hospitalization for heart failure (HHF) by 35% vs placebo, on the EMPA- REG OUTCOME trial, which showed a bmjdrc-2020-001313 each on top of standard of care (SoC).
    [Show full text]
  • Effect of Ipragliflozin, an SGLT2 Inhibitor, on Cardiac Histopathological T Changes in a Non-Diabetic Rat Model of Cardiomyopathy ⁎ Toshiyuki Takasu , Shoji Takakura
    Life Sciences 230 (2019) 19–27 Contents lists available at ScienceDirect Life Sciences journal homepage: www.elsevier.com/locate/lifescie Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological T changes in a non-diabetic rat model of cardiomyopathy ⁎ Toshiyuki Takasu , Shoji Takakura Drug Discovery Research, Astellas Pharma Inc., Tsukuba-shi, Ibaraki, Japan ARTICLE INFO ABSTRACT Keywords: Aims: We investigated the effect of the selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor Sodium-dependent glucose cotransporter 2 ipragliflozin on cardiac dysfunction and histopathology in a non-diabetic rat model of cardiomyopathy. Ipragliflozin L-proline (PubChem CID: Main methods: Ipragliflozin was mixed with chow (0.01%, w/w) and administered to male DahlS.Z-Leprfa/Leprfa 57339444) (DS/obese) rats for 8 weeks. Male DahlS.Z-Lepr+/Lepr+ (DS/lean) rats of the same age were used as controls. Cardio-protective effect Systolic blood pressure (SBP) and heart rate (HR) were measured every 4 weeks. After 8 weeks of treatment, echocardiography and histopathological examinations were performed. Further, the effect of ipragliflozin on blood and urine parameters were investigated. Key findings: In the DS/obese rats, ipragliflozin delayed the age-related increase in SBP without affecting HR, reduced left ventricular (LV) mass and intraventricular septal thickness in echocardiography, and ameliorated hypertrophy of cardiomyocytes and LV fibrosis in histopathological examination. Although ipragliflozin sig- nificantly increased both urine volume and urinary glucose excretion in DS/obese rats, it did not alterplasma glucose levels. Significance: Ipragliflozin prevented LV hypertrophy and fibrosis in non-diabetic DS/obese rats without affecting plasma glucose levels. These findings suggest that SGLT2 inhibitors have a cardio-protective effect in non-dia- betic patients with cardiomyopathy.
    [Show full text]
  • Identification of SGLT2 Inhibitor Ertugliflozin As a Treatment
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.18.448921; this version posted June 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Identification of SGLT2 inhibitor Ertugliflozin as a treatment for COVID-19 using computational and experimental paradigm Shalini SaxenaA, Kranti MeherC, Madhuri RotellaC, Subhramanyam VangalaC, Satish ChandranC, Nikhil MalhotraB, Ratnakar Palakodeti B, Sreedhara R Voleti A*, and Uday SaxenaC* A In Silico Discovery Research Academic Services (INDRAS) Pvt. Ltd. 44-347/6, Tirumalanagar, Moula Ali, Hyderabad – 500040, TS, India B Tech Mahindra Gateway Building, Apollo Bunder, Mumbai-400001, Maharashtra, India C Reagene Innovation Pvt. Ltd. 18B, ASPIRE-BioNEST, 3rd Floor, School of Life Sciences, University of Hyderabad, Gachibowli, Hyderabad – 500046, TS, India *Corresponding Authors email address: [email protected] [email protected] Abstract Drug repurposing can expedite the process of drug development by identifying known drugs which are effective against SARS-CoV-2. The RBD domain of SARS-CoV-2 Spike protein is a promising drug target due to its pivotal role in viral-host attachment. These specific structural domains can be targeted with small molecules or drug to disrupt the viral attachment to the host proteins. In this study, FDA approved Drugbank database were screened using a virtual screening approach and computational chemistry methods. Five drugs were short listed for further profiling based on docking score and binding energies. Further these selected drugs were tested for their in vitro biological activity.
    [Show full text]